RPG Life Sciences Limited has informed the Exchange about Investor Presentation
June 02, 2025
To
The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051
BSE Limited Corporate Relationship Department 25, P.J. Towers, Dalal Street, Mumbai 400 001
Symbol: RPGLIFE
Scrip Code: 532983
Dear Sir/Madam,
Sub: Investor Presentation
In continuation to our Letter dated May 29, 2025, and pursuant to Regulation 30 of SEBI (Listing
Obligation and Disclosure Requirements) Regulation, 2015, we enclosed herewith the Investor’s
Presentation which will be made during RPG Annual Investor Conference 2025 scheduled to be held on
June 03, 2025.
Kindly take the same on record.
Thanking you,
Yours faithfully, For RPG Life Sciences Limited
Rajesh Shirambekar Head – Legal & Company Secretary
Encl: As above
hello happiness
RPG Annual Investor Conference 2025 RPG Life Sciences
June 3, 2025
Disclaimer
This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements. The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice. This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.
2
RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.
APIs 14%
International Formulations (IF) 20%
Domestic Formulations (DF)
Develop, manufacture and market branded formulations in India & Nepal
Domestic Formulations(DF) 66%
International Formulations (IF)
Develop, manufacture and market oral solid dosage formulations in the generics and branded generics space
APIs
Develop, manufacture and sell high value synthetic APIs in the general therapeutic category
Leader in Immunosuppressants
9 Therapies represented by High Equity Brands
50+ Markets Presence
3 Manufacturing Facilities
1300+ Employees
RPG Life Sciences: Product Portfolio Strong ‘Textbook’ brands ; ↑ Chronic and Specialty therapies
Key Therapies
Nephrology
Rheumatology
Oncology
Pain Management
Gastroenterology
Neuropsychiatry
Cardio- Diabeto
Urology
Legacy Portfolio
Immunosuppressants
Textbook Brands
Azathioprine
Azathioprine
Spironolactone
Mycophenolate Mofetil
Diphenoxylate HCl
Cyclosporine
Tacrolimus
Naproxen
Haloperidol
Life Cycle Management (Existing Products)
DF Key Products
New Portfolio
Specialty
Chronic
Trastuzumab
Adalimumab
Bevacizumab
Rituximab
Tofacitinib
Sacubitril+ Valsartan
Vildagliptin
Teneligliptin
Dapagliflozin
Solifenacin
Disopyramide Phosphate
Ferric Carboxymaltose
Denosumab
IF Key Products Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzantil, Dipsope
APIs Key Products Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole
FY25 delivered a strong all-round performance
↑ Sales Growth
↑ EBITDA Growth
↑ Margin
↑ ROCE *
12.3%
27.3%
+ 312 bps
32.9%
↑ ROE *
↑ EPS *
↑ Volume Growth
↑ Market Capitalization
24.3%
Rs. 67.5
6.6%
+49%
* Excluding impact of exceptional items
Profit Margins: A Trajectory of y-o-y expansion continues un-interrupted
Significant upward trajectory across all margin metrics
26.4%
23.0%
EBITDA %
PBT %*
17.1%
PAT%*
23.3%
20.2%
15.1%
20.3%
16.6%
11.7%
21.0%
17.9%
13.2%
18.2%
13.8%
10.3%
15.9%
11.1%
7.7%
8.7%
4.2% 4.2%
9.3%
4.7% 3.9%
11.1%
5.9%
3.9%
10.4%
4.6% 3.3%
FY 16
FY 17
FY 18
FY 19
FY 20
FY21
FY22
FY23
FY24
FY25
* Excluding impact of exceptional items
6
Revenues, Profit, Cashflows: A strong y-o-y upward trajectory continues unabated
Revenue Up by 12% vs LY
PBT* up by 28% vs LY
653.4
582.1
512.8
440.2
375.6 389.1
330.2
150.3
117.8
91.7
73.2
53.6
36.5
15.1
Rs. crores
Significant cash balance* (from operations)
168.2
127.6
115.2
70.3
40.3
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY19
FY20
FY21
FY22
FY23
FY24 FY25 *
FY20 FY19 -14.5 -3.9
FY21
FY22
FY23
FY24
FY25
Revenue ~2x v/s FY19
PBT ~10X v/s FY19
Continue to have zero debt in FY25
* Excluding impact of exceptional items
Key Financial Ratios: A trajectory of y-o-y uptrend continues unabated
EPS*
ROCE %*
ROE %*
67.5
31.6% 32.9%
29.7%
28.5%
53.0
40.9
24.9%
20.9%
24.3%
23.4%
22.0%
20.1%
18.5%
16.4%
31.1
24.2
17.5
6.5
9.7%
6.7%
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY19
FY20
FY21
FY22
FY23
FY24
FY25
EPS ~10x v/s FY19
ROCE improved by 2320 bps v/s FY19
ROE improved by 1760 bps v/s FY19
* Excluding impact of exceptional items
ROCE = (PBT + Finance Cost)/ Capital Employed; ROE = PAT / Total Equity (i.e. post tax)
RPG Lifesciences Market Cap outperforming the benchmark over the past 5 Years
18.0
16.0
14.0
12.0
10.0
8.0
6.0
4.0
2.0
0.0
Apr-20
Aug-20
Dec-20
Apr-21
Aug-21
Dec-21
Apr-22
Aug-22
Dec-22
Apr-23
Aug-23
Dec-23
Apr-24
Aug-24
Dec-24
RPG Lifesciences
BSE Healthcare
BSE Sensex
13.2x
3.5x 2.7x
Continued strengthening of our balance sheet in FY25
Improvements recorded in ICRA Rating
Factors affecting rating affirmation
• Long term rating
reaffirmed at A+ and outlook retained as stable
• Short term rating reaffirmed at A1
• A robust capital structure and strong debt servicing
indicators based on
o Healthy cash flows o Company continues to remain debt-free o No debt-funded capital expenditure (capex)
• Steady growth in Top-line and improving operating
margins
• Strong brands in the Indian Pharmaceutical
Industry
• Expansion of product portfolio and geographical
presence augur well for growth prospects
8 Strategic initiatives enabling our strong performance
1
2
3
4
5
6
7
8
Business Transformation & improving margin profile
Constant focus on implementing projects to build cost efficiencies across multiple projects which has resulted in EBITDA% moving from 23.3% in FY24 to 26.4% in FY25
Comprehensive Life Cycle Management of Legacy products
Naprosyn crosses Rs. 76 crores in FY25 - on its way to become first 100 crore brand; multiple engagement initiatives driving SoV, depth and breadth of Rx support
Foray into New Therapies and new product launches
The new rheumatology franchise grows to contribute 14% to specialty business; foray into ortho and critical care in FY25
Focus on cashflow generation to invest into driving next wave of growth
Significant surplus cash flow of Rs. 267 crores in FY25; opportunities to drive inorganic growth of our business being evaluated
Factories, R&D, Regulatory Gearing Up to support Frontend
Capex of ~ INR 140 crores to modernise plants and R&D infrastructure
Quality enhancement projects
Multiple projects underway for audit-based quality enhancement; TGA and EUGMP certification renewal obtained in FY25
All round Performance Recognition
Multiple Awards/Recognitions – Best Patent, Best CSR, Best Brand, Best Company, Best Values-in-action; Amongst Top 500 Value creators of India
Happiness Initiatives driving Happy Performance driven Culture
Happiness Score 88%|Ranked #2 amongst RPG group companies
Continued focus on delivering environmental-friendly growth
41% carbon emission reduction in FY25
52% reduction in hazardous waste management in FY25
41% increase in energy efficiency in FY25
7% reduction in water consumption
RPGLS Journey Ahead: 7 strategic pillars of action
1
2
3
4
5
6
7
Portfolio development and mega-brands building
• Project underway to grow our immunosuppressant portfolio to 200+ crores • Focused initiatives to grow Naprosyn to a 100+ crores brand; building our MABs portfolio
Growing our API business
• Focus on new geographies, new launch pipeline and enhancing manufacturing productivity • Focus on strengthening customer relationships and onboarding new high-value customers
Strong Digital Roadmap
• Multiple digital initiatives designed to streamline front-end and backend operations • Initiatives focus on improving efficiency & compliance, reducing costs and growing topline
Mergers & Acquisitions
• M&A Framework with criteria defined - target therapies, brands • Evaluation of multiple proposals underway to identify opportunities for growth synergy
New products across segments, new therapies
• Focused new product pipeline; lab modernization and org expansion complete • Strategy to evaluate and expand into adjacencies in RPGLS strength therapies
State-of-art capacity plants
• 140 crores capex infused since FY22 helped build modern plant with EU/PICS/TGA, etc. approval • Evaluation ongoing of varied opportunities for improving manufacturing productivity
Talent Development /Acquisition
• Org structure review & role/skill-gaps identification for strengthening • Talent development and talent acquisition across all key business and support functions
hello happiness